

10/634,489

- 2 -

PC25260A

**REMARKS**

Claims 1 to 17 are pending in the application.

***Restriction Requirement***

In the Office Action, it was alleged that Claims 1 to 17 are generic to a plurality of disclosed patentably distinct species comprising pyrans, thiomorpholine, and morpholines. Applicant is required under 35 U.S.C. § 121 to elect a single disclosed species.

It is not clear to Applicant from reading the Office Action in view of claim 1 what are the alleged patentably distinct inventions. However, Applicant desires to be fully responsive to the restriction requirement. Accordingly, Applicant elects the first single disclosed species of claim 12: 3-(3,5-difluoro-4-hydroxy-benzyl)-8-methyl-2,4-dioxo-1,2,3,4,7,8-hexahydro-pyrido[2,3-d]pyrimidine-6-carboxylic acid (2-methoxy-pyridin-4-ylmethyl)-amide. This species is a compound of claim 11 wherein Y<sup>5</sup> is N(R<sup>5</sup>).

In view of the above remarks, Applicants request consideration of claims 1 to 17.

Respectfully submitted,

Date: April 26, 2005

Claude F. Purchase, Jr.

Claude F. Purchase, Jr.

Reg. No. 47,871

Pfizer Inc.

2800 Plymouth Road

Ann Arbor, MI 48105

Tel. (734) 622-1692

Fax (734) 622-1553